Primus Patent-Cliff Exposure & CMS Drug Spending Portfolio

Primus (US): 3 reconciled FDA prescription therapies, $10.2M 2024 CMS Part D & Medicaid spend, and $3,750 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2035-01-01
2024 CMS Total Public Spend$10.2M
2024 Medicare Part D Spend$8.5M
2024 Medicaid Spend$1.7M
California HCAI SB 17 FilingsSpecialty launch notice ($3,750 intro WAC)